MATD3

Rede Mater Dei de Saúde is a Brazilian company dedicated to providing hospital and oncology services, with common shares traded on B3 under the ticker MATD3. Its origins date back to 1973, when it was founded by physician José Salvador Silva in Belo Horizonte. The first hospital unit, Hospital Mater Dei Santo Agostinho, was opened in 1980, marking the beginning of a trajectory of expanding clinical, technological, and infrastructure capacities. Throughout the 1980s, the institution established itself as a reference in mastology, with the creation of Unimater, and in pediatric intensive care, by implementing one of the first pediatric ICUs in the state of Minas Gerais. In 1989, one of the first successful in vitro fertilizations in the country reinforced the company’s positioning in reproductive medicine.

In the 1990s and 2000s, Rede Mater Dei intensified the professionalization of its management and expanded its hospital structure. In 1992, it joined the PAEX program of Fundação Dom Cabral, focused on management excellence, and in 1994 it began medical staff planning aligned with corporate strategy. The physical expansion of the Santo Agostinho Unit, including Block II and the implementation of a Day Hospital, was accompanied by the creation of in-house clinical pathology laboratories, expansion of diagnostic imaging services, and structuring of research ethics committees. From 2000 onward, the company intensified care and administrative standardization with programs such as the Qualitas Project, which resulted in hundreds of medical protocols and nursing processes, contributing to the achievement of national and international quality certifications.

Rede Mater Dei’s evolution increasingly incorporated hospital accreditation and clinical governance standards. In 2004, the hospital achieved the maximum level of the Organização Nacional de Acreditação (ONA III), becoming one of the first in Brazil with this recognition. Subsequently, it pursued international certifications such as ISO 9001, NIAHO, associated with the U.S. healthcare quality model, and later Joint Commission International (JCI) accreditation, obtained in 2016 by Mater Dei Contorno, the first hospital in Minas Gerais with this seal. In parallel, the company structured medical residency and health specialization programs, also establishing itself as a training center for professionals, integrated into a governance model that combines non-medical managers and physicians.

Rede Mater Dei de Saúde’s business model is based on operating general hospitals, oncology units, outpatient clinics, and clinical laboratories on an integrated platform of medical-hospital services. The company operates exclusively in the hospital services segment, recognizing its revenue mainly from hospitalizations, emergency room visits, surgeries, intensive therapies, oncology, diagnostic medicine, and outpatient services. The company offers more than 60 medical specialties in its units, structured to capture revenue at various links of the care chain, from imaging diagnostics and laboratory tests to highly complex procedures such as robotic surgeries, bone marrow transplants, and integrated oncology treatments. This model aims for scale gains and operational efficiency, with strong standardization of protocols and intensive use of clinical performance indicators.

In terms of service portfolio, Rede Mater Dei operates inpatient and adult and pediatric ICU units, surgical centers with dozens of operating rooms distributed across its units, 24-hour emergency rooms in multiple specialties, and its own outpatient clinics, such as Mais Saúde, focused on continuous care and management of chronic patients. The oncology area is organized around the Hospital Integrado do Câncer, designed for the exclusive care of oncology patients, with infrastructure that integrates clinical oncology, onco-hematology, pediatric oncology, oncogenetics, cardio-oncology, oncofertility, and bone marrow transplant, as well as advanced imaging services such as PET-CT. The company also maintains a Human Reproduction Center with assisted reproduction technologies in a hospital environment, and a diagnostic medicine complex that includes CT scanners, MRI equipment, mammography machines, hemodialysis devices, and other therapeutic and diagnostic support resources.

Rede Mater Dei de Saúde’s geographic and operational expansion has resulted in an approximate capacity of 2,200 hospital beds distributed across nine units, with about 1,200 operational beds. The company has consolidated a leading position in Minas Gerais, especially in the metropolitan region of Belo Horizonte, with units such as Santo Agostinho, Contorno, and Betim-Contagem, and, starting in 2019, it began a national expansion cycle with projects and acquisitions in other regions. Operations came to also cover cities such as Salvador, Feira de Santana, Uberlândia, and Goiânia, expanding the patient base across different regional markets. The construction and acquisition of new hospitals, combined with ongoing investments in medical technology, have contributed to the increase in the number of beds since the IPO in 2021, when the company more than doubled its installed capacity.

From a commercial standpoint, Rede Mater Dei maintains relationships with several health plan operators, insurers, and self-managed entities, such as Bradesco Saúde, Sul América, Amil, Allianz, Cassi, pension entities, and corporate plans of large groups. Revenue shows some concentration, with the largest client accounting for a significant share of net operating revenue, which makes contract management with operators and health plan administrators a central factor in the company’s economic dynamics. Operations are primarily geared toward middle- and high-income patients under supplemental health coverage, in a Brazilian market considered fragmented in terms of private hospital supply. Long-term relationships with operators and the maintenance of quality standards and hospital accreditations are important factors for the network’s inclusion and permanence in provider panels.

Rede Mater Dei de Saúde’s activities are strongly influenced by government regulation of the supplemental health sector and sanitary surveillance. The relationship with health plan operators is governed by rules issued by the Agência Nacional de Saúde Suplementar (ANS), which define parameters for coverage, price adjustment, contracts between operators and providers, and rules for replacing providers in accredited networks. In addition, the operation of hospitals, clinics, laboratories, and diagnostic services depends on licenses and permits granted by health authorities under the coordination of the Agência Nacional de Vigilância Sanitária (ANVISA), which regulates aspects such as sanitary safety, handling of biological materials, disposal of hospital waste, and use of radioactive materials. Compliance with these regulatory requirements is foundational for the operational continuity of the services provided by the network.

Rede Mater Dei de Saúde’s management incorporates corporate governance practices aligned with the Novo Mercado listing segment, with a board of directors and structured family succession. From a care perspective, the company operates with a focus on patient safety, monitoring clinical indicators through dashboards and committees involving the medical staff and executive management. The use of methodologies such as PDCA and the Quintuple Aim model of the Institute for Healthcare Improvement guides continuous improvement initiatives in care experience, population health, per capita cost, well-being of healthcare workers, and equity. The company also invests in internal training and leadership programs, such as the Centro de Formação Institucional and the Lidera Mater Dei program, as well as using digital platforms, such as the Meu Mater Dei app, for scheduling appointments, tracking surgeries, and accessing test results, integrating technology into clinical care and the management of the patient journey.

In the environmental, social, and governance (ESG) field, Rede Mater Dei de Saúde directs efforts toward efficient use of resources and alignment with sustainable practices, such as entering the free energy market, enabling the use of renewable sources. From a social standpoint, the company’s role stands out in training health professionals, offering residency and specialization programs, and adopting international patient safety protocols recommended by the World Health Organization and ANVISA. In governance, the combination of physician and non-physician managers, the structuring of boards, and adherence to corporate transparency standards reflect a model focused on business continuity and professional management of one of the country’s leading private hospital networks, publicly traded with MATD3 shares listed on B3.